Early detection. Proactive intervention.

$70\%$ ScvO$_2$
Edwards oximetry central venous catheter (CVC) — the first proven CVC with continuous ScvO₂ monitoring — reveals the true adequacy of tissue oxygenation for clarity in early assessment and intervention.⁶–¹⁰

Edwards oximetry central venous catheter continuously monitors central venous oxygen saturation (ScvO₂), an early indicator of compromised or inadequate oxygen delivery.⁶–¹⁰

Continuous ScvO₂ monitoring: Proactive management of tissue hypoxia⁶–¹⁰

By providing a more sensitive indicator of oxygen imbalance, Edwards oximetry central venous catheter identifies critical changes earlier than traditional vital signs and intermittent sampling — enabling you to recognize and prevent tissue hypoxia sooner.⁶–¹⁰

Hemodynamic trends

<table>
<thead>
<tr>
<th>ECG</th>
<th>MAP</th>
<th>CVP</th>
<th>SpO₂</th>
<th>ScvO₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>120</td>
<td>50</td>
<td>50</td>
<td>100</td>
<td>75</td>
</tr>
<tr>
<td>100</td>
<td>40</td>
<td>40</td>
<td>120</td>
<td>70</td>
</tr>
<tr>
<td>80</td>
<td>30</td>
<td>30</td>
<td>100</td>
<td>25</td>
</tr>
</tbody>
</table>

Root causes

- **CO**
  - Vasoactive medications
  - Inotropic medications
  - Dysrhythmia
  - Congestive heart failure
  - Shock

- **Hb**
  - Hemorrhage
  - Occult bleeding
  - Anemia
  - Hemodilution

- **SaO₂**
  - Hypoxia/hypoxemia
  - Suctioning, atelectasis
  - Ventilation/oxygenation
  - Lung disease

- **VO₂**
  - Sepsis
  - Work of breathing
  - Fever, shivering
  - Pain/anxiety

Continuous ScvO₂ monitoring reveals the root cause of oxygen imbalance, allowing you to determine appropriate therapy.⁶,²¹

Helps guide therapy and provide real-time insight into the efficacy of intervention.⁶,⁷

Demonstrated prognostic value of continuous ScvO₂ monitoring.¹¹
- Post-op high-risk surgeries¹²
- Trauma⁹
- Sepsis¹³
- Cardiac failure in congenital heart failure¹⁰
- Recovery in cardiac arrest¹⁴–¹⁵

Continuous ScvO₂ monitoring has multiple applications in intra- and post-op stages.¹⁶,¹⁷
- Risk for high blood loss, such as hepatic resections, trauma, vascular cases
- High fluid shifts in gastrointestinal cases
- Toleration of single-lung ventilation in thoracic procedures
- Early indication of failure to tolerate extubation
The advantages of antimicrobial protection and high-pressure injection, together in a single device.  

Oligon integrated antimicrobial protection
Integrated Oligon antimicrobial material provides enduring antimicrobial protection that will not wash away like antimicrobial coatings. Silver ions (Ag+) are released at a stable rate to attack microbes, alter cell DNA and disrupt cell reproduction. The resulting long-term release of silver into lumens and subcutaneous spaces protects against gram-negative and gram-positive bacteria, fungi and resistant microorganism strains.18,19,20

High-pressure injection capability
Edwards oximetry central venous catheter is indicated for high-pressure injection of contrast media for visualization under imaging modalities such as CT, MRI and fluoroscopy.18
For Oligon models only.

Convenient, accurate and easy to use.6,17,22

Edwards oximetry central venous catheter provides:

| Simplicity and flexibility — uses the same insertion techniques as central lines22 |
| Continuous ScvO₂ monitoring, pressure monitoring and fluid resuscitation²,18 |
| Accurate oxygenation status²,4 |

See advanced hemodynamic parameters with a new level of clarity.*

The HemoSphere advanced monitor from Edwards Lifesciences reimagines the way you see, experience and interact with hemodynamic parameters. A range of clinical-support screen choices provides a new level of visual clinical support, facilitating decision making during rapidly changing situations.

*Compared to Vigilance II monitor
See clearly. Stay ahead.

Designed for use with Edwards’ monitoring platforms, Edwards’ oximetry central venous catheters offer the clarity of an early warning to support early intervention.

Edwards oximetry central venous catheter

<table>
<thead>
<tr>
<th></th>
<th>Lumens</th>
<th>Length (CM)</th>
<th>Oligon</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>X3816KT</td>
<td>3</td>
<td>16</td>
<td>US</td>
<td></td>
</tr>
<tr>
<td>X3820KT</td>
<td>3</td>
<td>20</td>
<td>US</td>
<td></td>
</tr>
<tr>
<td>XA3816KT</td>
<td>3</td>
<td>16</td>
<td>X</td>
<td>US</td>
</tr>
<tr>
<td>XA3816SAKT</td>
<td>3</td>
<td>16</td>
<td>X</td>
<td>US</td>
</tr>
<tr>
<td>XA3820KT</td>
<td>3</td>
<td>20</td>
<td>X</td>
<td>US</td>
</tr>
<tr>
<td>XA3820SAKT</td>
<td>3</td>
<td>20</td>
<td>X</td>
<td>US</td>
</tr>
</tbody>
</table>

For over 40 years, Edwards Lifesciences has been helping you make proactive clinical decisions to advance the care of surgical and critical care patients.

Through ongoing collaboration with you, ongoing education and our never-ending quest for advancement, Edwards develops solutions that provide the clarity to make proactive clinical decisions.

Know more. Visit Edwards.com/OximetryCVC

CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards, Edwards Lifesciences, the stylized E logo, EV1000, HemoSphere, PediaSat, PreSep, and Vigilance II are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2017 Edwards Lifesciences Corporation. All rights reserved. PP--US-1956 v1.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com
References for Edwards oximetry central venous catheter brochure

1. Edwards Oximetry Central Venous Catheter Instructions for Use
3. FDA 510k K053609
4. FDA 510k K061585
5. FDA 510k K091786
18. FDA 510k Edwards Oximetry Central Venous Catheter (K160645)
19. US Patent #4411648
20. Edwards Oligon Oximetry Catheters contain an integrated Oligon antimicrobial material. The activity of the antimicrobial agent is localized at the catheter surfaces and is not intended for treatment of systemic infections. In vitro testing demonstrated that the Oligon material provided broad-spectrum effectiveness (≥ 3 log reduction from initial concentration within 48 hours) against the organisms tested: Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Enterococcus faecalis, Candida albicans, Escherichia coli, Serratia marcescens, Acinetobacter calcoaceticus, Corynebacterium diphtheriae, Enterobacter aerogenes, GMRSa, Pseudomonas aeruginosa, Candida glabrata and VRE (Enterococcus faecium).